{'fraction_non_alphanumeric': 0.04753521126760563, 'fraction_numerical': 0.04084507042253521, 'mean_word_length': 4.774390243902439, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical and Laboratory Experience with Erythrocyte and Platelet Preparations from a 0.5CPD Erythro‐Sol Opti System

Background: Red blood cells stored as concentrates or suspensions in additive solutions change rapidly their oxygen affinity mainly due to the loss of 2,3‐diphosphoglycerate (2,3‐DPG). When collected in CPD with half of the normal concentration of citrate and citric acid (0.5CPD) and stored in a new additive solution (Erythro‐Sol), 2,3‐DPG is better maintained. No studies of the oxygen affinity of red cells stored under these conditions have been published. In Erythro‐Sol, red cells have a satisfactory in vivo recovery for 49 days but the conditions after 28 days, within which time most red cell units are transfused, have not been investigated. Of importance is also to be able to make platelet concentrates (PCs) from 0.5CPD blood. Little data are available concerning the clinical usefulness of platelets prepared from 0.5CPD buffy coats (BCs). Methods: Blood was collected in 0.5CPD, held at 20°C for 3–4 h, then separated with the bottom‐and‐top technique into red cells, plasma and BC. In a storage experiment with 6 U the 2,3‐DPG and P50 values were determined weekly and a number of in vitro parameters were tested on day 28. In 6 donors the in vivo recovery and survival of red cells were determined using a single‐chromium technique. Transfusions of 212 0.5CPD‐Erythro‐Sol red cell units were given to hematological patients under supervision. PCs derived from pools of 0.5CPD BCs suspended in PAS2 (T‐Sol) were transfused to 20 thrombocytopenic patients and compared with CPD‐BC‐PCs suspended in PAS1. Corrected count increments (CCI) were determined. Results: The erythrocyte 2,3‐DPG and P50 values were normal or slightly subnormal initially but increased to supernormal levels during the 1 week, and remained at these levels for a further 1–3 weeks; the 2,3‐DPG was two thirds of normal after 28 days, the P50 was 3.72±0.28 kPa after 14 days and 2.84±0.41 after 28 days (mean ± SD). The P50 values corresponded closely (r2= 0.903) to 2,3‐DPG. The in vivo recovery of 4‐week‐stored red cells was 89.6±5.5% and the T50 was 32.2±2.0 days. No adverse effects were observed in the transfusions. The CCI values did not differ between test and control groups; in both, 3‐ to 5‐day‐stored PCs gave lower CCI than fresh (0–2 days) PCs. Patients with acute myeloid leukemia AML (n = 11) had significantly lower CCI values than patients with myelodysplastic syndrome, myeloma and lymphoma (n = 9; CCI1 h: p = 0.001; CCI24 h: p = 0.006). Conclusions: Red cells stored in Erythro‐Sol sustain a normal or slightly lowered oxygen affinity for 2–4 weeks, their viability is excellent, and they are well tolerated in clinical transfusions. Platelets prepared from 0.5CPD‐BCs cause CCls of the same magnitude as CPD‐BCs.